ImageneBio IMA
NASDAQ IMA
$4.09 -0.05 (-1.09%)
At close: Oct 21, 2026 · 4:00 PM EDT

ImageneBio (IMA) Preferred Stock Liabilities (2020 - 2023)

Updated

ImageneBio's Preferred Stock Liabilities was $31.85 million in Q3 2023.

Analysis

ImageneBio (IMA) Preferred Stock Liabilities (2020 - 2023) Analysis & Trends

At the end of FY2020, Preferred Stock Liabilities at ImageneBio came in at $205.98 million.

  • The Q3 2023 figure marks the highest quarterly Preferred Stock Liabilities since Q4 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 ImageneBio 34.70 Mn -452.92 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 31.85 Mn
Dec 31, 2020 205.98 Mn
Sep 30, 2020 78.87 Mn
Jun 30, 2020 78.87 Mn
Mar 31, 2020 78.87 Mn
API Access

ImageneBio Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=IMA&period=max&api_key=YOUR_API_KEY